Clincosm LogoSign in Get a demo

Carcinoma, Non-Small-Cell Lung

Showing 51 - 75 of 574
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors, NSCLC Trial in Worldwide (BI 754111, BI 754091)

Active, not recruiting
  • Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • BI 754111
  • BI 754091
  • Miami, Florida
  • +14 more
Jan 9, 2023

NSCLC, NSCLC, Nonsmall Cell Lung Cancer Trial in Saint Louis (Nintedanib)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 3, 2023

Malignant Melanoma, NSCLC, Brain Tumors, Primary Trial in United States (PF-07284890, Binimetinib, Midazolam)

Recruiting
  • Malignant Melanoma
  • +4 more
  • Duarte, California
  • +71 more
Dec 29, 2022

NSCLC Trial in Worldwide (INC280 (capmatinib))

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • INC280 (capmatinib)
  • Long Beach, California
  • +95 more
Dec 29, 2022

NSCLC Trial in Worldwide (Selpercatinib, Placebo)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Santa Monica, California
  • +206 more
Dec 27, 2022

NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Tuscaloosa, Alabama
  • +260 more
Dec 16, 2022

Stage III NSCLC RWE in Chinese Patients

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
    • BeiJing, China
    • +24 more
    Dec 14, 2022

    NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +13 more
    • furmonertinib 240 mg
    • +2 more
    • Yuma, Arizona
    • +37 more
    Dec 14, 2022

    NSCLC Trial in United States

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
      • Daphne, Alabama
      • +17 more
      Nov 30, 2022

      NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
      • +5 more
      • Duarte, California
      • +1 more
      Dec 7, 2022

      NSCLC Trial in China (Atezolizumab, Placebo, Bevacizumab)

      Active, not recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Beijing City, China
      • +22 more
      Dec 7, 2022

      NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Avitinib Maleate
      • +13 more
      • Guangzhou, Guangdong, China
        Guangdong Lung Cancer Institute, Guangdong Provincial People's H
      Dec 3, 2022

      Toward High Fidelity Adaptive Radiotherapy in the Thorax

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
      • CBCT-guided Adaptive Radiotherapy
      • (no location specified)
      Nov 30, 2022

      NSCLC Trial in Salvador, Belo Horizonte, São Paulo

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
        • Salvador, Bahia, Brazil
        • +3 more
        Nov 28, 2022

        Advanced Solid Tumor, Urinary Bladder Tumor, Pancreatic Tumors Trial in Worldwide (BT8009, Nivolumab)

        Recruiting
        • Advanced Solid Tumor
        • +4 more
        • Denver, Colorado
        • +20 more
        Nov 22, 2022

        NSCLC, Cutaneous Melanoma, Carcinoma, Renal Cell Trial (KFA115, tislelizumab)

        Recruiting
        • Carcinoma, Non-Small-Cell Lung
        • +10 more
        • Singapore, Singapore
          Novartis Investigative Site
        Nov 16, 2022

        RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

        Active, not recruiting
        • RET-altered Non Small Cell Lung Cancer
        • +39 more
        • pralsetinib (BLU-667)
        • Phoenix, Arizona
        • +65 more
        Nov 10, 2022

        NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

        Terminated
        • Carcinoma, Non-Small-Cell Lung
        • Maastricht, Limburg, Netherlands
        • +4 more
        Nov 7, 2022

        NSCLC Trial in Guangzhou (Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin)

        Recruiting
        • Carcinoma, Non-Small-Cell Lung
        • Guangzhou, Guang Dong, China
          Sun Yat-sen University Cancer Center
        Nov 3, 2022

        NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

        Not yet recruiting
        • Carcinoma, Non-Small-Cell Lung
        • Carcinoma Breast
        • Suzhou, China
          Second Affiliated Hospital of Soochow University
        Oct 29, 2022

        Nivolumab, Ipilimumab, and Chemotherapy in Non-small Cell Lung

        Not yet recruiting
        • Carcinoma, Non-Small-Cell Lung
          • Athens, Greece
            Local Institution - 0001
          Oct 26, 2022

          NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)

          Recruiting
          • Carcinoma, Non-Small-Cell Lung
          • +8 more
          • New Haven, Connecticut
            Yale University
          Oct 26, 2022

          Usage of Brigatinib in Treatment of Adult Approved Indications

          Recruiting
          • Carcinoma, Non-Small-Cell Lung
          • Anaplastic Lymphoma Kinase
          • No Intervention
          • Busan, Korea, Republic of
            Pusan National University Hospital
          Oct 19, 2022

          NSCLC Trial in Boston, New York (MPDL3280A, Carboplatin, Nab-paclitaxel)

          Completed
          • Carcinoma, Non-Small-Cell Lung
          • Boston, Massachusetts
          • +1 more
          Oct 12, 2022

          Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

          Recruiting
          • Lung Neoplasms
          • +23 more
          • La Jolla, California
          • +35 more
          Oct 6, 2022